I'll be stacking https://t.co/Yzx4gDBF4Gmert | helius.dev (@0xMert_):the bull case for ZEC is AOC ...

bull case for SOL is that it's the most usable, battle-tested network with the greatest concentration of engineering, product, and consumer talent, with a clear way of capturing the value it generates without fragmentationbasically robinhood at global scale on steroids ...

Core Thesis - UnitedHealth Group Incorporated (UNH) is viewed positively despite recent challenges, with a potential for recovery as operational normalization and regulatory clarity emerge [4]. Company Overview - UNH has a market capitalization of $312 billion and a P/E ratio of 15, positioning it as a leading diversified healthcare conglomerate that provides health insurance, pharmacy care, and care delivery through its Optum division [2]. - The stock was trading at $353.72 as of October 2nd, with trailing and forward P/E ratios of 15.31 and 20.08 respectively [1]. Recent Performance - UNH's stock has faced significant pressure, down 32% year-to-date and 45% from its 2024 all-time high, due to rising medical costs, lower profitability, and scrutiny from a DOJ investigation [2][3]. - The company is actively addressing these challenges, including implementing pricing adjustments to stabilize the medical loss ratio [3]. Strategic Response - UNH is cooperating fully with the DOJ investigation, indicating a limited financial impact from this scrutiny [3]. - The company's diversified business model and scale in care delivery through Optum provide resilience and long-term growth potential [3]. Investment Opportunity - The combination of a depressed stock price, strong underlying fundamentals, and active management response creates an attractive risk/reward profile for investors [4]. - UNH is seen as a compelling opportunity for those willing to look beyond near-term volatility, with the market potentially underestimating its capacity to stabilize margins and resume profitable growth [4].

Core Thesis - Protagonist Therapeutics, Inc. (PTGX) presents a compelling investment opportunity due to strong clinical progress and underappreciated fundamentals, with a market cap of $3.6 billion and $615 million in net cash as of June 2025 [2][4] Clinical Assets - PTGX's most valuable asset, Icotrokinra (Ico), is an oral IL-23R peptide antagonist partnered with JNJ, nearing FDA approval with robust Phase 2/3 data for multiple indications including psoriasis and Crohn's disease [2][3] - Ico's efficacy rivals or potentially surpasses injectable treatments like Skyrizi and Tremfya, positioning PTGX to capture significant market share in a $25 billion IL-23 class [3] Financial Projections - PTGX is projected to earn $400–$900 million in annual royalties from Ico, with additional upside from sales milestones and market expansion, leading to a plausible base-case DCF value of $3–4 billion [3][5] - Rusfertide, another asset partnered with Takeda, targets polycythemia vera and is expected to generate $100–$200 million in annual cash flow, along with a $400 million opt-out payment [3][4] Strategic Positioning - PTGX's platform includes oral IL-17, oral hepcidin, and obesity drug candidates, providing high optionality and potential for significant future upside [4] - The company has a strong balance sheet with minimal burn relative to upcoming catalysts, and management incentives are aligned with shareholder value [4] Market Catalysts - Multiple catalysts exist, including Ico approval and Rusfertide commercialization decisions, which the market has yet to fully price in [4][5] - The potential for strategic transactions, such as royalty sales or platform acquisitions, could further unlock value for PTGX [5]